
    
      The clinical trial is a prospective, randomized, controlled, two-arm, single-blind study,
      involving 118 patients affected by symptomatic OA of the knee joint. Eligible subjects will
      be randomly allocated to one of the two treatment groups, with a 1:1 randomization ratio.
      Respectively, 59 patients treated with a single intra-articular injection of aMAT, and 59
      patients treated with a single intra-articular injection of PRP.

      The patients enrolled in the study will be treated according to the study protocol and
      followed after treatment with periodic visits and diagnostic imaging examinations, as
      Magnetic Resonance Imaging at twelve and twenty-four months follow-up and X-Ray, at three,
      six, twelve, and twenty-four months of follow-up.
    
  